- Preliminary findings of a real-world study showed that benralizumab significantly reduced exacerbation rates in patients with severe eosinophilic asthma (SEA), including those with chronic rhinosinusitis with nasal polyps (CRwNP).
Why this matters
- Although the safety and efficacy of benralizumab have been established in phase 3 trials, its real-world data are limited.
- Interim analysis (n=61) of the multicentre retrospective ANANKE study which evaluates the clinical characteristics and asthma exacerbations in patients with SEA receiving 12 weeks of benralizumab treatment.
- The median follow-up duration was 9.3 (interquartile range, 6.1-11.7) months.
- Annualized exacerbation rates (AER) were assessed before and after the first injection of benralizumab (index date).
- Funding: AstraZeneca.
- 34.4% of the patients had CRwNP in the past year.
- The AER was 4.98 for any exacerbation and 1.25 for severe exacerbations during the year before the index date.
- At follow-up, the AER decreased to 0.38 for any exacerbation (reduction of 92.4%) and 0.08 for severe exacerbations (reduction of 93.6%).
- The study is ongoing.
- Retrospective design.